Pharmaceutical manufacturers of Thioctic acid

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

Sinopharm, a significant healthcare organization affiliated with the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, operates with a workforce of 128,000 and a comprehensive industry presence encompassing research and development, production, supply chain management, retail outlets, medical services, engineering, events, international trade, and financial services. It possesses more than 1,100 subsidiaries and 6 publicly traded companies, including Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., and China National Accord Medicines Corporation Ltd.

SCL was incorporated on December 20, 1993, as a Private Limited Company. Initially, it manufactured intermediates. On July 1, 1997, the company became a Public Limited Company and adopted its current name. In 2004, SCL established a new API manufacturing facility. Today, it offers a wide range of APIs and advanced intermediates in various therapeutic segments such as NSAIDs, cardiology, anti-cholinergic, CNS, anti-filarials, and anthelmintics, among others, to its customers. We are based in Panchkula, near Chandigarh, with two manufacturing facilities in Derabassi, Mohali (Punjab), for intermediates and APIs. The marketing office is located in Delhi NCR. We have acquired 22 acres of land for expanding facilities near the current site.

Established in the year 2000 as Dongwoo Shintech Co., Ltd., INIST ST has emerged as a pioneer in the advancement of pharmaceutical raw materials and the technology for synthesizing raw materials. Guided by the principles of transformation, innovation, and a passion for life, INIST ST has been engaged in the exploration and production of high-caliber generic raw materials and enhanced drugs through salt modification, commencing with the development of treatments for cerebrovascular diseases and distributing them both nationally and globally. Backed by unwavering trust and expertise, it is utilized as a contrast agent for heart disease and serves as the basis for numerous original active ingredients.

KINSY is an independent chemical company, located in Murcia (Spain), having broad expertise in development, scale-up and commercial production of fine chemicals, with a strong focus on development and manufacturing of key pharmaceutical intermediates and APIs under cGMP.

Jiangsu Tonghe Pharmaceutical Co., Ltd. and Changshu Wanxing Chemical Co., Ltd. are wholly-owned affiliates of Jiangsu Wanxing Venture Capital Co., Ltd. They are a nationally recognized technology firm that integrates the exploration and development, manufacturing, and distribution of pharmaceutical products, raw materials, and nutritional supplements. For 8 consecutive years, it has maintained a position among the top 50 of the leading 100 businesses in Changshu City.